Page last updated: 2024-12-11
tnp 351
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
TNP 351: a novel antifolate being evaluated for chemotherapy of lung cancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5487322 |
| SCHEMBL ID | 5300564 |
| MeSH ID | M0209445 |
Synonyms (19)
| Synonym |
|---|
| tnp 351 |
| (2s)-2-[[4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]pentanedioic acid |
| l-glutamic acid, n-(4-(3-(2,4-diamino-1h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)- |
| 48go5za420 , |
| 125991-51-7 |
| tnp-351 |
| n-(4-(3-(2,4-diamino-1h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)-l-glutamic acid |
| unii-48go5za420 |
| n-(4-(3-(2,4-diamino-7h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)glutamic acid |
| l-glutamic acid, n-(4-(3-(2,4-diamino-7h-pyrrolo(2,3-d)pyrimidin-5-yl)propyl)benzoyl)- |
| SCHEMBL5300564 |
| DTXSID30155032 |
| n-{4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl}-l-glutamic acid |
| (4-(3-(2,4-diamino-1h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)benzoyl)-l-glutamic acid |
| CS-0014801 |
| Q27259143 |
| HY-19095 |
| l-glutamic acid, n-[4-[3-(2,4-diamino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]- |
| AKOS040747542 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The test drug was used on dosage schedules of single and daily doses for 5 or 3 days (by intravenous drip over 30 minutes, respectively)." | ( [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Akazawa, S; Furue, H; Hasegawa, K; Kanamaru, R; Niitani, H; Sasaki, T; Taguchi, T; Tominaga, T; Tsukagoshi, S; Yoneda, S, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 2 (25.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||